For people with significant hair loss from alopecia areata, this daily pill can produce major, durable regrowth over 2 years for most people who respond -- but it carries real, if infrequent, risks (shingles, serious infections, rare cancer and cardiovascular events) that need ongoing medical monitoring rather than a 'set and forget' approach.
What they did
Followed patients with severe alopecia areata taking ritlecitinib 50 mg/day for up to 2 years (104 weeks) in an open-label extension study, tracking scalp, eyebrow, and eyelash regrowth alongside side effects.
What they found
By month 24 (observed data), 73.5% of patients had 20% or less scalp hair loss remaining (SALT≤20) and 66.4% had 10% or less remaining; 82.4% reported meaningful overall improvement; eyebrows regrew in 60.8% and eyelashes in 65.7% of patients. On safety: 86.1% had some adverse event (mostly mild-to-moderate), 4.9% had a serious adverse event, and 6.5% stopped the drug due to side effects; rarer events included 6 cases of shingles, 4 serious infections, 3 cancers, and 3 major cardiovascular events.
Limitations
Open-label with no placebo comparison group for this long-term phase, making it hard to fully rule out natural fluctuation in alopecia areata (which can spontaneously improve); sponsored and run by the drug manufacturer (Pfizer); results reported as 'observed' (only in patients still in the study) looked notably better than 'last observation carried forward' analyses that account for dropouts.
Who paid for it
Pfizer Inc. (drug manufacturer)
Read the original
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study ↗ · Tziotzios C, Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Tsianakas A, Luo X, Law EH, Ishowo-Adejumo R, Wolk R, Sadrarhami M, Lejeune A · DOI 10.1111/jdv.20526
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.